A practical and successful desensitization protocol for immediate hypersensitivity reactions to iron salts.
Orally administered iron salts (OAS) are widely used in the management of iron deficiency anemia and hypersensitivity reactions to OAS are not common. If an offending drug is the sole option or is significantly more effective than its alternatives, it can be readministered by desensitization. The oral desensitization protocols for iron published so far concern either desensitization that was completed only over a long period or did not attain the recommended therapeutic dose. We aimed to develop a more effective protocol. We report here on 2 patients who experienced hypersensitivity reactions to OAS. After confirming the diagnosis, both patients were desensitized to oral ferrous (II) glycine sulfate complex according to a 2-day desensitization protocol. A commercial suspension of oral ferrous glycine sulfate, which contains 4 mg of elemental iron in 1 ml, was preferred. We started with a dose as low as 0.1 ml from a 1/100 dilution (0.004 mg elemental iron) of the original suspension and reached the maximum effective dose in 2 days. Both patients were successfully desensitized and they went on to complete the 6-month iron treatment without any adverse effects. Although hypersensitvity reactions to iron are not common, there is no alternative for iron administration. Therefore, desensitization has to be the choice. This easy desensitization protocol seems to be a promising option.
Division of Allergy, Department of Internal Medicine, Istanbul University Faculty of Medicine, Istanbul, Turkey.
Semra
S
Demir
Muge
M
Olgac
Derya
D
Unal
Asli
A
Gelincik
Bahauddin
B
Colakoglu
Suna
S
Buyukozturk
D000328:Adult; D000368:Aged; D018798:Anemia, Iron-Deficiency / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D003888:Desensitization, Immunologic / Q000379:methods; D004342:Drug Hypersensitivity / Q000175:diagnosis / Q000276:immunology* / Q000628:therapy*; D005260:Female; D005296:Ferrous Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000175:diagnosis / Q000276:immunology* / Q000628:therapy*; D007501:Iron / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D012492:Salts / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome
D005296:Ferrous Compounds; D012492:Salts; C020748:ferrous sulfate; D007501:Iron